182 related articles for article (PubMed ID: 12571214)
1. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.
Kostakoglu L; Goldsmith SJ
J Nucl Med; 2003 Feb; 44(2):224-39. PubMed ID: 12571214
[TBL] [Abstract][Full Text] [Related]
2. Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.
Kubota K; Matsuno S; Morioka N; Adachi S; Koizumi M; Seto H; Kojo M; Nishioka S; Nishimura M; Yamamoto H
Ann Nucl Med; 2015 Jun; 29(5):431-41. PubMed ID: 25812534
[TBL] [Abstract][Full Text] [Related]
3. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic value of FDG-PET.
Geus-Oei LF; Oyen WJ
Cancer Imaging; 2008 Mar; 8(1):70-80. PubMed ID: 18390390
[TBL] [Abstract][Full Text] [Related]
5. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.
Hicks RJ
J Nucl Med; 2009 May; 50 Suppl 1():31S-42S. PubMed ID: 19380411
[TBL] [Abstract][Full Text] [Related]
6. [Current status of 18F-FDG PET in predicting outcome of cancer therapy].
Gong HY; Yu JM
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):577-80. PubMed ID: 16429617
[No Abstract] [Full Text] [Related]
7. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.
Hicks RJ; Kalff V; MacManus MP; Ware RE; Hogg A; McKenzie AF; Matthews JP; Ball DL
J Nucl Med; 2001 Nov; 42(11):1596-604. PubMed ID: 11696627
[TBL] [Abstract][Full Text] [Related]
8. 18-Fluorodeoxyglucose positron emission tomography as a tool for response prediction in solid tumours.
De Maeseneer DJ; Lambert B; Surmont V; Geboes K; Rottey SW
Acta Clin Belg; 2010; 65(5):291-9. PubMed ID: 21128554
[TBL] [Abstract][Full Text] [Related]
9. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of therapy for lymphoma.
Jerusalem G; Hustinx R; Beguin Y; Fillet G
Semin Nucl Med; 2005 Jul; 35(3):186-96. PubMed ID: 16098292
[TBL] [Abstract][Full Text] [Related]
11. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.
Hicks RJ; Kalff V; MacManus MP; Ware RE; McKenzie AF; Matthews JP; Ball DL
J Nucl Med; 2001 Nov; 42(11):1605-13. PubMed ID: 11696628
[TBL] [Abstract][Full Text] [Related]
12. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
13. Application of a neural network to improve nodal staging accuracy with 18F-FDG PET in non-small cell lung cancer.
Vesselle H; Turcotte E; Wiens L; Haynor D
J Nucl Med; 2003 Dec; 44(12):1918-26. PubMed ID: 14660717
[TBL] [Abstract][Full Text] [Related]
14. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
15. Use of a dual-head coincidence camera and 18F-FDG for detection and nodal staging of non-small cell lung cancer: accuracy as determined by 2 independent observers.
Stevens H; Bakker PF; Schlösser NJ; van Rijk PP; de Klerk JM
J Nucl Med; 2003 Mar; 44(3):336-40. PubMed ID: 12620997
[TBL] [Abstract][Full Text] [Related]
16. PET imaging in breast cancer.
Bombardieri E; Crippa F
Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
[TBL] [Abstract][Full Text] [Related]
17. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
19. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
[TBL] [Abstract][Full Text] [Related]
20. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
